Quetiapine Fumarate
Product Images NDC 0406-1183

This is a medication guide for Quetiapine Fumarate, an extended-release tablet, which is only available through a prescription. Each tablet contains 173mg of Quetiapine Fumarate and 1509mg of Getapre. The medication should be stored below 25°C and excursions from 15-30°C are permitted. The usual dosage is one tablet alongside the prescription of a doctor.*

This is a medication guide for Quetiapine Fumarate, with each tablet containing 230mg of Quetiapine. The tablets are extended-release and should be swallowed whole once daily. The usual dosage, along with warnings and storage instructions, are included. The manufacturer is Intellipharmaceutics Corp, and the distributor is SpecGx LLC, with a reference to Mallinckrodt Pharmaceuticals.*

This is a medication guide for Quetiapine Fumarate Extended-Release Tablets USP. The tablets come in 345 mg dose and are equivalent to 300 mg of quetiapine. The guide includes instructions to swallow the tablets whole and not to crush or chew them. The usual dosage is once daily, as per the accompanying prescribing information. The guide includes a warning to keep the medication out of the reach of children, and to store it at controlled room temperature (25°C/77°F) with excursions permitted up to 15-30°C (59-86°F). The tablets are manufactured by Intelipharmaceutics Corp. and distributed by SpecGx LLC, and the medication is available through prescription only by Mallinckrodt Pharmaceuticals.*

This is a medication called "quetiapine fumarate" that comes in a bottle with 60 tablets each containing 56 mg of the medication. Patients must be given a medication guide with the prescription and swallow the tablets whole. The usual dosage is once daily, as directed in the prescribing information. The medication must be stored at a temperature of 31-25°C (1°F), with excursions permitted up to 15-30°C (52.6°F). This medication is manufactured by Inelighamaceutcs Co. SpecGxLLC.*

This is a graph showing the proportion of patients with relapse over time in weeks. The percentage of patients with relapse is consistently at 100%.*